Why Pfizer Is Still a Top Stock for 2021
In recent weeks, we've seen waves of good news taking a variety of stocks to all-time highs. But there's one healthcare stalwart that hasn't benefited: Pfizer (NYSE: PFE). Despite the successes of the past few months, including the release and rapid distribution of the company's COVID vaccine and impressive growth in its other therapeutics, Pfizer has fallen off its all-time high of $42.60 a share on Dec. 8 and into a very attractive valuation. I want to show you why this pharma giant deserves a place in your portfolio and should be a stable holding for the long term.
Image Source: Getty Images.
Pfizer is one of the four iconic leaders of American pharmaceuticals, along with Johnson & Johnson, Merck, and Bristol Myers Squibb. Since its founding in 1849, Pfizer's 170-year-plus journey has included the development of several breakthrough drugs that have succeeded not just domestically, but internationally as well. Over the past few decades, Pfizer has been the name behind such well-known products as Advil, Bextra, Diflucan, and Viagra, not to mention some big names in consumer health, including Chapstick and Preparation H. And in 2020, Pfizer partnered with German company BioNTech to create a COVID vaccine.
Source Fool.com
